COMPANY

Prana Therapies, Inc.

“Prana is advancing a wholly owned pipeline of multispecific therapeutics, initially focused on respiratory and dermatologic diseases, with discovery-stage programs expanding across therapeutic areas.” Source · checked Oct 13, 2026

Keywords: clinical-stage antibodies antibody Phase 1 Phase 2 respiratory

Location: Encinitas, CA · source · Oct 13, 2026

Profile checked Oct 13, 2026

1 sourcedFunding itemssee sources below

Sourced facts

Each item links to its source and was checked by an independent review on Oct 13, 2026 (San Diego batch).

Focus / stage (company wording)

clinical-stage · pranatherapies.com · checked Oct 13, 2026

Headquarters address

Encinitas, CA · sec.gov · checked Oct 13, 2026

Funding (company or press release)

Total Amount Sold $ 40,226,932 · sec.gov · checked Oct 13, 2026

ClinicalTrials.gov

NCT07810777 · clinicaltrials.gov · checked Oct 13, 2026

Funding and NIH signals

SEC Form D raise Raised $40.23M (Form D filed Aug 10, 2026). SEC Form D 0001231919-26-000849 (Aug 10, 2026)
Evidence (1 event)
- Aug 10, 2026 · SEC Form D 0001231919-26-000849
  Name of Issuer: Prana Therapies, Inc.; CIK: 2029240; Address: Encinitas, CA; Submission type: D; Filing date: 2026-08-10; Industry Group: Biotechnology; Date of First Sale: 2025-11-25; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 40226932; Total Amount Sold: 40226932; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals